A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

Inclusion Criteria: * patients with malignant bone disease; * patients with moderate to severe pain. Exclusion Criteria: * patients who have received a bisphosphonate within 3 weeks from the signing of the informed consent; * patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing; * untreated esophagitis or gastric ulcers; * recent or pre-scheduled radiotherapy to bone; * patients who are pregnant or breast-feeding.